摘要
目的观察布地奈德/福莫特罗粉吸入剂(信必可都保)不同剂量治疗中-重度慢性阻塞性肺疾病(COPD)稳定期患者的疗效。方法入选2009年2月至2012年12月来我院就诊的中-重度COPD稳定期患者,随机分为A、B、C组。A组(对照组)给予常规治疗,B组在常规治疗基础上加吸常规剂量信必可都保160μg/4.5μg,1吸/次,2次/d,C组在常规治疗基础上加吸大剂量信必可都保160μg/4.5μg,2吸/次,2次/d。评估各组治疗前、治疗3月和6月后的肺功能、临床症状评分,治疗期间急性加重人数及药物不良反应。结果 B、C组的总有效率优于A组(P<0.05),C组与B组间无统计学差异(P>0.05)。结论信必可都保吸入剂能改善中-重度COPD稳定期患者的临床症状及肺功能,大剂量组与常规剂量组间疗效无统计学差异,但不良反应显著高于常规剂量组。
Objective To observe the effects of different doses of budesonide/formoterol fumarate in the treatment for moderate to severe COPD in stable phase. Methods The patients with moderate to severe COPD from February 2009 to December 2012 in this hospital were selected and randomly divided into group A,B and C. Group A was given conventional therapy. Group B was given standard-dose budesonide / formoterol fumarate of 160 μg /4. 5 μg on basis of conventional therapy,one inhalation,twice per day. Group C was given large-dose budesonide / formoterol fumarate of 160 μg /4. 5 μg on basis of conventional therapy,two inhalations,twice per day. The lung function,clinical symptoms score,the number of the patients showing acute exacerbations of COPD during treatment and the side effects were evaluated before treatment,3 months and 6 months after treatment respectively. Results The total of effective results rate in group B and C was higher than that of group A( P < 0. 05); There was no statistical difference between group B and group C( P > 0. 05). Conclusions Budesonide /formoterol fumarate could improve the clinical symptoms and lung function of the patients with moderate to severe COPD in stable phase. The large dose shows no better effect,but induces more significant side effects.
出处
《实用老年医学》
CAS
2013年第11期930-932,共3页
Practical Geriatrics
